<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33971585</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9157</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><PubDate><Year>2021</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of autoimmunity</Title><ISOAbbreviation>J Autoimmun</ISOAbbreviation></Journal><ArticleTitle>An autoantigen profile of human A549 lung cells reveals viral and host etiologic molecular attributes of autoimmunity in COVID-19.</ArticleTitle><Pagination><StartPage>102644</StartPage><MedlinePgn>102644</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaut.2021.102644</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-8411(21)00052-4</ELocationID><Abstract><AbstractText>We aim to establish a comprehensive COVID-19 autoantigen atlas in order to understand autoimmune diseases caused by SARS-CoV-2 infection. Based on the unique affinity between dermatan sulfate and autoantigens, we identified 348 proteins from human lung A549&#xa0;cells, of which 198 are known targets of autoantibodies. Comparison with current COVID data identified 291 proteins that are altered at protein or transcript level in SARS-CoV-2 infection, with 191 being known autoantigens. These known and putative autoantigens are significantly associated with viral replication and trafficking processes, including gene expression, ribonucleoprotein biogenesis, mRNA metabolism, translation, vesicle and vesicle-mediated transport, and apoptosis. They are also associated with cytoskeleton, platelet degranulation, IL-12 signaling, and smooth muscle contraction. Host proteins that interact with and that are perturbed by viral proteins are a major source of autoantigens. Orf3 induces the largest number of protein alterations, Orf9 affects the mitochondrial ribosome, and they and E, M, N, and Nsp proteins affect protein localization to membrane, immune responses, and apoptosis. Phosphorylation and ubiquitination alterations by viral infection define major molecular changes in autoantigen origination. This study provides a large list of autoantigens as well as new targets for future investigation, e.g., UBA1, UCHL1, USP7, CDK11A, PRKDC, PLD3, PSAT1, RAB1A, SLC2A1, platelet activating factor acetylhydrolase, and mitochondrial ribosomal proteins. This study illustrates how viral infection can modify host cellular proteins extensively, yield diverse autoantigens, and trigger a myriad of autoimmune sequelae. Our work provides a rich resource for studies into "long COVID" and related autoimmune sequelae.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Julia Y</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA. Electronic address: julia@curandis.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Affiliated Hospital of Guizhou Medical University, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Michael W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Victor B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Curandis, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roehrl</LastName><ForeName>Michael H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: roehrlm@mskcc.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA008748</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 CA251992</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Autoimmun</MedlineTA><NlmUniqueID>8812164</NlmUniqueID><ISSNLinking>0896-8411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001324">Autoantigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>bioRxiv. 2021 Feb 22:2021.02.21.432171. doi: 10.1101/2021.02.21.432171</RefSource><PMID Version="1">33655248</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000072283" MajorTopicYN="N">A549 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001324" MajorTopicYN="N">Autoantigens</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="Y">Autoimmunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atlas</Keyword><Keyword MajorTopicYN="N">Autoantigens</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Lung</Keyword><Keyword MajorTopicYN="N">Resource</Keyword></KeywordList><CoiStatement>JYW is the founder and Chief Scientific Officer of Curandis. WZ was supported by the NIH and declares no competing interests. MWR and VBR are volunteers of Curandis. MHR is a member of the Scientific Advisory Boards of Trans-Hit, Proscia, and Universal DX, but these companies have no relation to the study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>10</Day><Hour>20</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33971585</ArticleId><ArticleId IdType="mid">NIHMS1698722</ArticleId><ArticleId IdType="pmc">PMC8075847</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2021.102644</ArticleId><ArticleId IdType="pii">S0896-8411(21)00052-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang J.Y., Zhang W., Roehrl M.W., Roehrl V.B., Roehrl M.H. bioRxiv; 2021. An Autoantigen Atlas from Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19. 20210124427965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8987778</ArticleId><ArticleId IdType="pubmed">35401574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.Y., Lee J., Yan M., Rho J.H., Roehrl M.H. Dermatan sulfate interacts with dead cells and regulates CD5(+) B-cell fate: implications for a key role in autoimmunity. Am. J. Pathol. 2011;178:2168&#x2013;2176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081202</ArticleId><ArticleId IdType="pubmed">21514431</ArticleId></ArticleIdList></Reference><Reference><Citation>Rho J.H., Zhang W., Murali M., Roehrl M.H., Wang J.Y. Human proteins with affinity for dermatan sulfate have the propensity to become autoantigens. Am. J. Pathol. 2011;178:2177&#x2013;2190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081203</ArticleId><ArticleId IdType="pubmed">21514432</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Rho J.-h., Roehrl M.H., Wang J.Y. 2021. Dermatan Sulfate Is a Potential Master Regulator of IgH via Interactions with Pre-BCR, GTF2I, and BiP ER Complex in Pre-B Lymphoblasts. bioRxiv 20210118427153.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185350</ArticleId><ArticleId IdType="pubmed">34113352</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J.Y., Zhang W., Rho J.H., Roehrl M.W., Roehrl M.H. A proteomic repertoire of autoantigens identified from the classic autoantibody clinical test substrate HEp-2 cells. Clin. Proteonomics. 2020;17:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7507713</ArticleId><ArticleId IdType="pubmed">32973414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Rho J.H., Roehrl M.H., Wang J.Y. A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins. BMC Immunol. 2019;20:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6595630</ArticleId><ArticleId IdType="pubmed">31242852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Rho J.H., Roehrl M.W., Roehrl M.H., Wang J.Y. A repertoire of 124 potential autoantigens for autoimmune kidney diseases identified by dermatan sulfate affinity enrichment of kidney tissue proteins. PloS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6592568</ArticleId><ArticleId IdType="pubmed">31237920</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S., Jones-Lopez E.C., Soneji D.J., Azevedo C.J., Patel V.R. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J. Neuro Ophthalmol. : the official journal of the North American Neuro-Ophthalmology Society. 2020;40:398&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382408</ArticleId><ArticleId IdType="pubmed">32604245</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles L., Platton S., Yartey N., Dave M., Lee K., Hart D.P., et al. Lupus anticoagulant and abnormal coagulation tests in patients with covid-19. N. Engl. J. Med. 2020;383:288&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217555</ArticleId><ArticleId IdType="pubmed">32369280</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber C.N., Patel R.S., Trachtman R., Lepow L., Amanat F., Krammer F., et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C) Cell. 2020;183:982&#x2013;995. e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagiannis D., Steinestel J., Hackenbroch C., Schreiner B., Hannemann M., Bloch W., et al. Clinical, serological, and histopathological similarities between severe COVID-19 and acute exacerbation of connective tissue disease-associated interstitial lung disease (CTD-ILD) Front. Immunol. 2020;11:587517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566417</ArticleId><ArticleId IdType="pubmed">33123171</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerma L.A., Chaudhary A., Bryan A., Morishima C., Wener M.H., Fink S.L. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19) Journal of translational autoimmunity. 2020;3:100073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691817</ArticleId><ArticleId IdType="pubmed">33263103</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujii H., Tsuji T., Yuba T., Tanaka S., Suga Y., Matsuyama A., et al. High levels of anti-SSA/Ro antibodies in COVID-19 patients with severe respiratory failure: a case-based review : high levels of anti-SSA/Ro antibodies in COVID-19. Clin. Rheumatol. 2020;39:3171&#x2013;3175.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7447083</ArticleId><ArticleId IdType="pubmed">32844364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dragonetti D., Guarini G., Pizzuti M. Detection of anti-heparin-PF4 complex antibodies in COVID-19 patients on heparin therapy. Blood transfusion = Trasfusione del sangue. 2020;18:328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375879</ArticleId><ArticleId IdType="pubmed">32697931</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., et al. Science; New York, NY): 2020. Autoantibodies against Type I IFNs in Patients with Life-Threatening COVID-19; p. 370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhou B., Pache L., Chang M., Khodabakhshi A.H., Tanaseichuk O., et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 2019;10:1523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6447622</ArticleId><ArticleId IdType="pubmed">30944313</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.Y., Wang X.M., Xing X., Xu Z., Zhang C., Song J.W., et al. Single-cell landscape of immunological responses in patients with COVID-19. Nat. Immunol. 2020;21:1107&#x2013;1118.</Citation><ArticleIdList><ArticleId IdType="pubmed">32788748</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies J.P., Almasy K.M., McDonald E.F., Plate L. Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus nonstructural proteins identifies unique and shared host-cell dependencies. ACS Infect. Dis. 2020;6:3174&#x2013;3189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724760</ArticleId><ArticleId IdType="pubmed">33263384</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann K., Bojkova D., Tascher G., Ciesek S., M&#xfc;nch C., Cinatl J. Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication. Mol. Cell. 2020;80 164-74.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418786</ArticleId><ArticleId IdType="pubmed">32877642</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Ye F., Wu A., Yang R., Pan M., Sheng J., et al. Comparative transcriptome analysis reveals the intensive early stage responses of host cells to SARS-CoV-2 infection. Front. Microbiol. 2020;11:593857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723856</ArticleId><ArticleId IdType="pubmed">33324374</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Klann K., Koch B., Widera M., Krause D., Ciesek S., et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583:469&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk A.J., Rustagi A., Zhao N.Q., Roque J., Mart&#xed;nez-Col&#xf3;n G.J., McKechnie J.L., et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020;26:1070&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman N.A.P., Peddu V., Xie H., Shrestha L., Huang M.L., Mears M.C., et al. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age. PLoS Biol. 2020;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7478592</ArticleId><ArticleId IdType="pubmed">32898168</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7603405</ArticleId><ArticleId IdType="pubmed">32707573</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouhaddou M., Memon D., Meyer B., White K.M., Rezelj V.V., Correa Marrero M., et al. The global phosphorylation landscape of SARS-CoV-2 infection. Cell. 2020;182:685&#x2013;712. e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7321036</ArticleId><ArticleId IdType="pubmed">32645325</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., M&#xf8;ller R., et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181 1036-45.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C., et al. Proteomic and metabolomic characterization of COVID-19 patient sera. Cell. 2020;182:59&#x2013;72. e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers M.M., Beumer J., van der Vaart J., Knoops K., Puschhof J., Breugem T.I., et al. vol. 369. Science; New York, NY): 2020. pp. 50&#x2013;54. (SARS-CoV-2 Productively Infects Human Gut Enterocytes).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7199907</ArticleId><ArticleId IdType="pubmed">32358202</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Y., Liu Y., Cao L., Wang D., Guo M., Jiang A., et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg. Microb. Infect. 2020;9:761&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170362</ArticleId><ArticleId IdType="pubmed">32228226</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A., Ralfs P., Chirkova T., Upadhyay A.A., Zimmerman M.G., Bedoya S., et al. Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J. Virol. 2020:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7495371</ArticleId><ArticleId IdType="pubmed">32699094</ArticleId></ArticleIdList></Reference><Reference><Citation>Appelberg S., Gupta S., Svensson Akusj&#xe4;rvi S., Ambikan A.T., Mikaeloff F., Saccon E., et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg. Microb. Infect. 2020;9:1748&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7473213</ArticleId><ArticleId IdType="pubmed">32691695</ArticleId></ArticleIdList></Reference><Reference><Citation>Stukalov A., Girault V., Grass V., Bergant V., Karayel O., Urban C., et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV. bioRxiv : the preprint server for biology. 2020:2020. 06.17.156455.</Citation></Reference><Reference><Citation>Emanuel W., Kirstin M., Vedran F., Asija D., Theresa G.L., Roberto A., et al. Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention. bioRxiv : the preprint server for biology. 2020:2020. 05.05.079194.</Citation></Reference><Reference><Citation>Li Y., Wang Y., Liu H., Sun W., Ding B., Zhao Y., et al. Urine proteome of COVID-19 patients. medRxiv. 2020:2020. 05.02.20088666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7933783</ArticleId><ArticleId IdType="pubmed">33688631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844.</Citation><ArticleIdList><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D., Gable A.L., Lyon D., Junge A., Wyder S., Huerta-Cepas J., et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47:D607&#x2013;D613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323986</ArticleId><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge S.X., Jung D., Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628&#x2013;2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7178415</ArticleId><ArticleId IdType="pubmed">31882993</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonin F., Ryan S.D., Migahed L., Mo F., Lallier J., Franks D.J., et al. Anti-apoptotic actions of the platelet-activating factor acetylhydrolase I alpha2 catalytic subunit. J. Biol. Chem. 2004;279:52425&#x2013;52436.</Citation><ArticleIdList><ArticleId IdType="pubmed">15456758</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C.S., Qi H.Y., Boularan C., Huang N.N., Abu-Asab M., Shelhamer J.H., et al. SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J. Immunol. 2014;193:3080&#x2013;3089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4179872</ArticleId><ArticleId IdType="pubmed">25135833</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang H.W., Zhang H.N., Meng Q.F., Xie J., Li Y., Chen H., et al. SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70. Cell. Mol. Immunol. 2020;17:998&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387808</ArticleId><ArticleId IdType="pubmed">32728199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibellini L., De Biasi S., Paolini A., Borella R., Boraldi F., Mattioli M., et al. Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol. Med. 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645870</ArticleId><ArticleId IdType="pubmed">33078545</ArticleId></ArticleIdList></Reference><Reference><Citation>Loke P., Hammond S.N., Leung J.M., Kim C.C., Batra S., Rocha C., et al. Gene expression patterns of dengue virus-infected children from Nicaragua reveal a distinct signature of increased metabolism. PLoS Neglected Trop. Dis. 2010;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886038</ArticleId><ArticleId IdType="pubmed">20559541</ArticleId></ArticleIdList></Reference><Reference><Citation>Karniely S., Weekes M.P., Antrobus R., Rorbach J., van Haute L., Umrania Y., et al. Human cytomegalovirus infection upregulates the mitochondrial transcription and translation machineries. mBio. 2016;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807356</ArticleId><ArticleId IdType="pubmed">27025248</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe1;ez-Santos Y.M., Mielech A.M., Deng X., Baker S., Mesecar A.D. Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J. Virol. 2014;88:12511&#x2013;12527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4248884</ArticleId><ArticleId IdType="pubmed">25142582</ArticleId></ArticleIdList></Reference><Reference><Citation>Freitas B.T., Durie I.A., Murray J., Longo J.E., Miller H.C., Crich D., et al. Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect. Dis. 2020;6:2099&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pubmed">32428392</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S.T., Yu G.Y., Lai M.M. Multiple type A/B heterogeneous nuclear ribonucleoproteins (hnRNPs) can replace hnRNP A1 in mouse hepatitis virus RNA synthesis. J. Virol. 2003;77:10584&#x2013;10593.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC228381</ArticleId><ArticleId IdType="pubmed">12970443</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkin L.B., Jessen B., Wiszniewski W., Vece T.J., Jan M., Sha Y., et al. COPA mutations impair ER-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis. Nat. Genet. 2015;47:654&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4513663</ArticleId><ArticleId IdType="pubmed">25894502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dieker J., Cisterna B., Monneaux F., Decossas M., van der Vlag J., Biggiogera M., et al. Apoptosis-linked changes in the phosphorylation status and subcellular localization of the spliceosomal autoantigen U1-70K. Cell Death Differ. 2008;15:793&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">18202700</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz P.J., Hottelet M., van Venrooij W.J., Anderson P. Association of phosphorylated serine/arginine (SR) splicing factors with the U1-small ribonucleoprotein (snRNP) autoantigen complex accompanies apoptotic cell death. J. Exp. Med. 1998;187:547&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2212144</ArticleId><ArticleId IdType="pubmed">9463405</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeifle J., Anderer F.A., Franke M. Multiple phosphorylation of human SS-B/LA autoantigen and its effect on poly(U) and autoantibody binding. Biochim. Biophys. Acta. 1987;928:217&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">2436670</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutjes S.A., Utz P.J., van der Heijden A., Broekhuis C., van Venrooij W.J., Pruijn G.J. The La (SS-B) autoantigen, a key protein in RNA biogenesis, is dephosphorylated and cleaved early during apoptosis. Cell Death Differ. 1999;6:976&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pubmed">10556975</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampieri S., Degen W., Ghiradello A., Doria A., van Venrooij W.J. Dephosphorylation of autoantigenic ribosomal P proteins during Fas-L induced apoptosis: a possible trigger for the development of the autoimmune response in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2001;60:72&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1753357</ArticleId><ArticleId IdType="pubmed">11114288</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders R.D., Nakajima S.T., Rai S.N., Pan J., Gercel-Taylor C., Taylor D.D. Alterations in antibody subclass immune reactivity to trophoblast-derived fetal fibronectin and &#x3b1;2-macroglobulin in women with recurrent pregnancy loss. Am. J. Reprod. Immunol. 2012;68:438&#x2013;449.</Citation><ArticleIdList><ArticleId IdType="pubmed">22935024</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrohai A., Nagy G., Bosze S., Hudecz F., Zsiros E., Paragh G., et al. Detection of citrate synthase-reacting autoantibodies after heart transplantation: an epitope mapping study. Transpl. Int. : official journal of the European Society for Organ Transplantation. 2005;17:834&#x2013;840.</Citation><ArticleIdList><ArticleId IdType="pubmed">15711981</ArticleId></ArticleIdList></Reference><Reference><Citation>Mande P.V., Parikh F.R., Hinduja I., Zaveri K., Vaidya R., Gajbhiye R., et al. Identification and validation of candidate biomarkers involved in human ovarian autoimmunity. Reprod. Biomed. Online. 2011;23:471&#x2013;483.</Citation><ArticleIdList><ArticleId IdType="pubmed">21890413</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beers J.J., Schwarte C.M., Stammen-Vogelzangs J., Oosterink E., Bozic B., Pruijn G.J. The rheumatoid arthritis synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen, and beta-actin. Arthritis Rheum. 2013;65:69&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">23044660</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanrotel-Saliou C., Segalen I., Le Meur Y., Youinou P., Renaudineau Y. Glomerular antibodies in lupus nephritis. Clin. Rev. Allergy Immunol. 2011;40:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">20414746</ArticleId></ArticleIdList></Reference><Reference><Citation>Bei R., Mizejewski G.J. Alpha-fetoprotein is an autoantigen in hepatocellular carcinoma and juvenile Batten disease. Front. Biosci. 2020;25:912&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">31585923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivner M.H., Quarles B.M., Pan J.X., Yu Z., Howard J.F., Jr., Corse A., et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study. Muscle Nerve. 2020;62:333&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496236</ArticleId><ArticleId IdType="pubmed">32483837</ArticleId></ArticleIdList></Reference><Reference><Citation>Prunotto M., Carnevali M.L., Candiano G., Murtas C., Bruschi M., Corradini E., et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2010;21:507&#x2013;519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831859</ArticleId><ArticleId IdType="pubmed">20150532</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehring J., Schirmbeck L.A., Friebus-Kardash J., Dubler D., Huynh-Do U., Chizzolini C., et al. Autoantibodies against albumin in patients with systemic lupus erythematosus. Front. Immunol. 2018;9:2090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6176020</ArticleId><ArticleId IdType="pubmed">30333817</ArticleId></ArticleIdList></Reference><Reference><Citation>Edassery S.L., Shatavi S.V., Kunkel J.P., Hauer C., Brucker C., Penumatsa K., et al. Autoantigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure. Fertil. Steril. 2010;94:2636&#x2013;2641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2948062</ArticleId><ArticleId IdType="pubmed">20522323</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng K.C., Wu Y.J., Cheng K.H., Cheng K.Y., Chen K.J., Wu W.C., et al. Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2018;256:1195&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">29397435</ArticleId></ArticleIdList></Reference><Reference><Citation>Privitera D., Corti V., Alessio M., Volont&#xe8; M.A., Lampasona V., Comi G., et al. Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders. Neurol. Sci. : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2013;34:313&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pubmed">22391679</ArticleId></ArticleIdList></Reference><Reference><Citation>Pott M.C., Frede N., Wanders J., Hammarstr&#xf6;m L., Glocker E.O., Glocker C., et al. Autoantibodies against BAFF, APRIL or IL21 - an alternative pathogenesis for antibody-deficiencies? BMC Immunol. 2017;18:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485583</ArticleId><ArticleId IdType="pubmed">28651547</ArticleId></ArticleIdList></Reference><Reference><Citation>Caster D.J., Korte E.A., Merchant M.L., Klein J.B., Wilkey D.W., Rovin B.H., et al. Autoantibodies targeting glomerular annexin A2 identify patients with proliferative lupus nephritis. Proteonomics Clin. Appl. 2015;9:1012&#x2013;1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4690797</ArticleId><ArticleId IdType="pubmed">25824007</ArticleId></ArticleIdList></Reference><Reference><Citation>Scholz P., Auler M., Brachvogel B., Benzing T., Mallman P., Streichert T., et al. Detection of multiple annexin autoantibodies in a patient with recurrent miscarriages, fulminant stroke and seronegative antiphospholipid syndrome. Biochem. Med. 2016;26:272&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910275</ArticleId><ArticleId IdType="pubmed">27346975</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh A., Suzuki K., Takayama E., Kojima K., Hidaka T., Kawakami M., et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J. Rheumatol. 1999;26:1715&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pubmed">10451067</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrycek A., Cie&#x15b;lik P. Annexin A5 and anti-annexin antibodies in patients with systemic lupus erythematosus. Rheumatol. Int. 2012;32:1335&#x2013;1342.</Citation><ArticleIdList><ArticleId IdType="pubmed">21298269</ArticleId></ArticleIdList></Reference><Reference><Citation>Seko Y., Matsumoto A., Fukuda T., Imai Y., Fujimura T., Taka H., et al. A case of neonatal lupus erythematosus presenting delayed dilated cardiomyopathy with circulating autoantibody to annexin A6. Int. Heart J. 2007;48:407&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">17592206</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarius S., Wildemann B. 'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J. Neuroinflammation. 2015;12:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4573944</ArticleId><ArticleId IdType="pubmed">26377319</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y., Kawaguchi Y., Baba S., Hattori S., Tahara K., Ito K., et al. Identification of three new autoantibodies associated with systemic lupus erythematosus using two proteomic approaches. Mol. Cell. Proteomics : MCP. 2011;10 M110.005330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108835</ArticleId><ArticleId IdType="pubmed">21474795</ArticleId></ArticleIdList></Reference><Reference><Citation>Krishnan B., Massilamany C., Basavalingappa R.H., Gangaplara A., Rajasekaran R.A., Afzal M.Z., et al. Epitope mapping of SERCA2a identifies an antigenic determinant that induces mainly atrial myocarditis in A/J mice. J. Immunol. 2018;200:523&#x2013;537. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760440</ArticleId><ArticleId IdType="pubmed">29229678</ArticleId></ArticleIdList></Reference><Reference><Citation>Creaney J., Dick I.M., Yeoman D., Wong S., Robinson B.W. Auto-antibodies to &#x3b2;-F1-ATPase and vimentin in malignant mesothelioma. PloS One. 2011;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3195718</ArticleId><ArticleId IdType="pubmed">22022619</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutgen V.M., Schmelter C., Pfeiffer N., Grus F.H. Autoantigens in the trabecular meshwork and glaucoma-specific alterations in the natural autoantibody repertoire. Clinical &amp; translational immunology. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7049230</ArticleId><ArticleId IdType="pubmed">32140226</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishore U., Sontheimer R.D., Sastry K.N., Zappi E.G., Hughes G.R., Khamashta M.A., et al. The systemic lupus erythematosus (SLE) disease autoantigen-calreticulin can inhibit C1q association with immune complexes. Clin. Exp. Immunol. 1997;108:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1904655</ArticleId><ArticleId IdType="pubmed">9158084</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber C.K., Haslbeck M., Englbrecht M., Sehnert B., Mielenz D., Graef D., et al. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology. 2010;49:2255&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">20716673</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W.H., Zhao J., Li H.Y., Liu H., Li A.L., Wang H.X., et al. Proteomics-based identification of autoantibodies in the sera of healthy Chinese individuals from Beijing. Proteomics. 2006;6:4781&#x2013;4789.</Citation><ArticleIdList><ArticleId IdType="pubmed">16878294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai K., Maeda H., Omori K., Yamamoto T., Kokeguchi S., Takashiba S. Serum antibody response to group II chaperonin from Methanobrevibacter oralis and human chaperonin CCT. Pathogens and disease. 2013;68:12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">23620386</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M., Kuribayashi K., Takahashi Y., Kondoh T., Tanaka M., Kobayashi D., et al. Identification of autoantibodies expressed in acquired aplastic anaemia. Br. J. Haematol. 2013;160:359&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">23116149</ArticleId></ArticleIdList></Reference><Reference><Citation>Vece T.J., Watkin L.B., Nicholas S., Canter D., Braun M.C., Guillerman R.P., et al. Copa syndrome: a novel autosomal dominant immune dysregulatory disease. J. Clin. Immunol. 2016;36:377&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4842120</ArticleId><ArticleId IdType="pubmed">27048656</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia M.C., Zhou J., Henning D., Arnett F.C., Valdez B.C. Unique epitopes in RNA helicase II/Gu protein recognized by serum from a watermelon stomach patient. Mol. Immunol. 2000;37:351&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">11074253</ArticleId></ArticleIdList></Reference><Reference><Citation>Scofield R.H. Do we need new autoantibodies in lupus? Arthritis Res. Ther. 2010;12:120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2911855</ArticleId><ArticleId IdType="pubmed">20537203</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai L., Li J., Tsay J.J., Yie T.A., Munger J.S., Pass H., et al. Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer. OncoImmunology. 2017;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5467997</ArticleId><ArticleId IdType="pubmed">28638733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim E.G., Kwak S.H., Hwang D., Yi E.C., Park K.S., Koo B.K., et al. The level of autoantibodies targeting eukaryote translation elongation factor 1 &#x3b1;1 and ubiquitin-conjugating enzyme 2L3 in nondiabetic young adults. Diabetes Metab. J. 2016;40:154&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4853223</ArticleId><ArticleId IdType="pubmed">26616590</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney C.J., Dunphy E.J., Stone B., McNeel D.G. Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis. Int. J. Urol. 2006;13:211&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">16643611</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Madrid F., Tang N., Alansari H., Granda J.L., Tait L., Amirikia K.C., et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Canc. Res. 2004;64:5089&#x2013;5096.</Citation><ArticleIdList><ArticleId IdType="pubmed">15289310</ArticleId></ArticleIdList></Reference><Reference><Citation>Bach M., Winkelmann G., Luhrmann R. 20S small nuclear ribonucleoprotein U5 shows a surprisingly complex protein composition. Proc. Natl. Acad. Sci. U. S. A. 1989;86:6038&#x2013;6042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297770</ArticleId><ArticleId IdType="pubmed">2527369</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo C.K., Hwang H.M., Lee H.J., Kwak S.S., Yoo J.S., Yu D.Y., et al. Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma. Sci. Rep. 2019;9:11059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6667438</ArticleId><ArticleId IdType="pubmed">31363116</ArticleId></ArticleIdList></Reference><Reference><Citation>Betteridge Z., Chinoy H., Vencovsky J., Winer J., Putchakayala K., Ho P., et al. Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology. 2020;59:1026&#x2013;1030.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7188460</ArticleId><ArticleId IdType="pubmed">31728542</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagaza-Straffon C., Marchat L.A., Herrera L., D&#xed;az-Ch&#xe1;vez J., Avante M.G., Rodr&#xed;guez Y.P., et al. Evaluation of a panel of tumor-associated antigens in breast cancer. Canc. Biomarkers : section A of Disease markers. 2020;27:207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">31839604</ArticleId></ArticleIdList></Reference><Reference><Citation>Moscato S., Pratesi F., Sabbatini A., Chimenti D., Scavuzzo M., Passatino R., et al. Surface expression of a glycolytic enzyme, alpha-enolase, recognized by autoantibodies in connective tissue disorders. Eur. J. Immunol. 2000;30:3575&#x2013;3584.</Citation><ArticleIdList><ArticleId IdType="pubmed">11169399</ArticleId></ArticleIdList></Reference><Reference><Citation>Akatsuka T., Kobayashi N., Ishikawa T., Saito T., Shindo M., Yamauchi M., et al. Autoantibody response to microsomal epoxide hydrolase in hepatitis C and A. J. Autoimmun. 2007;28:7&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1892246</ArticleId><ArticleId IdType="pubmed">17296285</ArticleId></ArticleIdList></Reference><Reference><Citation>Leveque C., Hoshino T., David P., Shoji-Kasai Y., Leys K., Omori A., et al. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc. Natl. Acad. Sci. U. S. A. 1992;89:3625&#x2013;3629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC48921</ArticleId><ArticleId IdType="pubmed">1314395</ArticleId></ArticleIdList></Reference><Reference><Citation>Capello M., Cappello P., Linty F.C., Chiarle R., Sperduti I., Novarino A., et al. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J. Hematol. Oncol. 2013;6:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3844582</ArticleId><ArticleId IdType="pubmed">24010981</ArticleId></ArticleIdList></Reference><Reference><Citation>Desmetz C., Bascoul-Mollevi C., Rochaix P., Lamy P.J., Kramar A., Rouanet P., et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin. Canc. Res. : an official journal of the American Association for Cancer Research. 2009;15:4733&#x2013;4741.</Citation><ArticleIdList><ArticleId IdType="pubmed">19584157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamhieh-Milz J., Sterzer V., Celik H., Khorramshahi O., Fadl Hassan Moftah R., Salama A. Identification of novel autoantigens via mass spectroscopy-based antibody-mediated identification of autoantigens (MS-AMIDA) using immune thrombocytopenic purpura (ITP) as a model disease. Journal of proteomics. 2017;157:59&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">28137667</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi-Hayama M., Adachi A., Shinozaki N., Matsutani T., Hiwasa T., Takiguchi M., et al. Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas. BMC Canc. 2014;14:452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094678</ArticleId><ArticleId IdType="pubmed">24946857</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X., Yang M., Sun H., L&#xfc; J., Zheng Z., Li Z., et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. OncoTargets Ther. 2013;6:273&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3615893</ArticleId><ArticleId IdType="pubmed">23569391</ArticleId></ArticleIdList></Reference><Reference><Citation>Terrier B., Tamby M.C., Camoin L., Guilpain P., Broussard C., Bussone G., et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2008;177:1128&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">18276943</ArticleId></ArticleIdList></Reference><Reference><Citation>Kit Y., Starykovych M., Vajrychova M., Lenco J., Zastavna D., Stoika R. Detection of novel auto-antigens in patients with recurrent miscarriage: description of an approach and preliminary findings. Croat. Med. J. 2014;55:259&#x2013;264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049207</ArticleId><ArticleId IdType="pubmed">24891284</ArticleId></ArticleIdList></Reference><Reference><Citation>Delunardo F., Soldati D., Bellisario V., Berry A., Camerini S., Crescenzi M., et al. Anti-GAPDH autoantibodies as a pathogenic determinant and potential biomarker of neuropsychiatric diseases. Arthritis &amp; rheumatology (Hoboken, NJ) 2016;68:2708&#x2013;2716.</Citation><ArticleIdList><ArticleId IdType="pubmed">27213890</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiyota A., Iwama S., Sugimura Y., Takeuchi S., Takagi H., Iwata N., et al. Identification of the novel autoantigen candidate Rab GDP dissociation inhibitor alpha in isolated adrenocorticotropin deficiency. Endocr. J. 2015;62:153&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pubmed">25346144</ArticleId></ArticleIdList></Reference><Reference><Citation>Massa O., Alessio M., Russo L., Nardo G., Bonetto V., Bertuzzi F., et al. Serological Proteome Analysis (SERPA) as a tool for the identification of new candidate autoantigens in type 1 diabetes. Journal of proteomics. 2013;82:263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">23500132</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlsson L., Ronquist G., Nilsson B.O., Larsson A. Dominant prostasome immunogens for sperm-agglutinating autoantibodies of infertile men. J. Androl. 2004;25:699&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pubmed">15292099</ArticleId></ArticleIdList></Reference><Reference><Citation>Muraki Y., Matsumoto I., Chino Y., Hayashi T., Suzuki E., Goto D., et al. Glucose-6-phosphate isomerase variants play a key role in the generation of anti-GPI antibodies: possible mechanism of autoantibody production. Biochem. Biophys. Res. Commun. 2004;323:518&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pubmed">15369782</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Tezel G., Patil R.V., Romano C., Wax M.B. Serum autoantibody against glutathione S-transferase in patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 2001;42:1273&#x2013;1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">11328739</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin R.L., Bell S.A., Burlingame R.W. Autoantibodies associated with lupus induced by diverse drugs target a similar epitope in the (H2A-H2B)-DNA complex. J. Clin. Invest. 1992;90:165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC443077</ArticleId><ArticleId IdType="pubmed">1378852</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlingame R.W., Boey M.L., Starkebaum G., Rubin R.L. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J. Clin. Invest. 1994;94:184&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC296296</ArticleId><ArticleId IdType="pubmed">8040259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wesierska-Gadek J., Penner E., Lindner H., Hitchman E., Sauermann G. Autoantibodies against different histone H1 subtypes in systemic lupus erythematosus sera. Arthritis Rheum. 1990;33:1273&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pubmed">2390129</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova S.V., Dmitrienok P.S., Ivanisenko N.V., Buneva V.N., Nevinsky G.A. Antibodies to H2a and H2b histones from the sera of HIV-infected patients catalyze site-specific degradation of these histones. Mol. Biosyst. 2017;13:1090&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">28426042</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruschi M., Galetti M., Sinico R.A., Moroni G., Bonanni A., Radice A., et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2015;26:1905&#x2013;1924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520170</ArticleId><ArticleId IdType="pubmed">25398787</ArticleId></ArticleIdList></Reference><Reference><Citation>van Bavel C.C., Dieker J., Muller S., Briand J.P., Monestier M., Berden J.H., et al. Apoptosis-associated acetylation on histone H2B is an epitope for lupus autoantibodies. Mol. Immunol. 2009;47:511&#x2013;516.</Citation><ArticleIdList><ArticleId IdType="pubmed">19747733</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranova S.V., Dmitrenok P.S., Zubkova A.D., Ivanisenko N.V., Odintsova E.S., Buneva V.N., et al. Antibodies against H3 and H4 histones from the sera of HIV-infected patients catalyze site-specific degradation of these histones. J. Mol. Recogn. : JMR (J. Mol. Recognit.) 2018;31</Citation><ArticleIdList><ArticleId IdType="pubmed">29457292</ArticleId></ArticleIdList></Reference><Reference><Citation>Konig M.F., Giles J.T., Nigrovic P.A., Andrade F. Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. Ann. Rheum. Dis. 2016;75:2022&#x2013;2028.</Citation><ArticleIdList><ArticleId IdType="pubmed">26865600</ArticleId></ArticleIdList></Reference><Reference><Citation>Heegaard N.H., Larsen M.R., Muncrief T., Wiik A., Roepstorff P. Heterogeneous nuclear ribonucleoproteins C1/C2 identified as autoantigens by biochemical and mass spectrometric methods. Arthritis Res. 2000;2:407&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC17817</ArticleId><ArticleId IdType="pubmed">11056675</ArticleId></ArticleIdList></Reference><Reference><Citation>Op De Be&#xe9;ck K., Maes L., Van den Bergh K., Derua R., Waelkens E., Van Steen K., et al. Heterogeneous nuclear RNPs as targets of autoantibodies in systemic rheumatic diseases. Arthritis Rheum. 2012;64:213&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">21905010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Fujimoto M., Murota H., Serada S., Fujimoto M., Honda H., et al. Proteomic identification of heterogeneous nuclear ribonucleoprotein K as a novel cold-associated autoantigen in patients with secondary Raynaud's phenomenon. Rheumatology. 2015;54:349&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pubmed">25172934</ArticleId></ArticleIdList></Reference><Reference><Citation>Hassfeld W., Chan E.K., Mathison D.A., Portman D., Dreyfuss G., Steiner G., et al. Molecular definition of heterogeneous nuclear ribonucleoprotein R (hnRNP R) using autoimmune antibody: immunological relationship with hnRNP P. Nucleic Acids Res. 1998;26:439&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC147279</ArticleId><ArticleId IdType="pubmed">9421497</ArticleId></ArticleIdList></Reference><Reference><Citation>Harlow L., Rosas I.O., Gochuico B.R., Mikuls T.R., Dellaripa P.F., Oddis C.V., et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65:869&#x2013;879.</Citation><ArticleIdList><ArticleId IdType="pubmed">23400887</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H.Y., Mahon J.L., Atkinson M.A., Chaturvedi P., Lee-Chan E., Singh B. Type 1 diabetes alters anti-hsp90 autoantibody isotype. J. Autoimmun. 2003;20:237&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">12753809</ArticleId></ArticleIdList></Reference><Reference><Citation>Cid C., Regidor I., Alcazar A. Anti-heat shock protein 90beta antibodies are detected in patients with multiple sclerosis during remission. J. Neuroimmunol. 2007;184:223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">17161872</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki S., Utsugisawa K., Iwasa K., Satoh T., Nagane Y., Yoshikawa H., et al. Autoimmunity to endoplasmic reticulum chaperone GRP94 in myasthenia gravis. J. Neuroimmunol. 2011;237:87&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">21774995</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi&#x161;unov&#xe1; M., Svit&#xe1;lkov&#xe1; T., Ple&#x161;tilov&#xe1; L., Kry&#x161;tufkov&#xe1; O., Tegzov&#xe1; D., Svobodov&#xe1; R., et al. Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development. Clin. Exp. Rheumatol. 2017;35:33&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">28032847</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu F., Schaller K.L., Owens G.P., Cotleur A.C., Kellner D., Takeshita Y., et al. Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica. Sci. Transl. Med. 2017;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585784</ArticleId><ArticleId IdType="pubmed">28679661</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone A., Giorgianni F., New D.D., Hollingsworth T.J., Umfress A., Alhatem A.H., et al. Circulating autoantibodies in age-related macular degeneration recognize human macular tissue antigens implicated in autophagy, immunomodulation, and protection from oxidative stress and apoptosis. PloS One. 2015;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4696815</ArticleId><ArticleId IdType="pubmed">26717306</ArticleId></ArticleIdList></Reference><Reference><Citation>Papp D., Proh&#xe1;szka Z., Kocsis J., F&#xfc;st G., B&#xe1;nhegyi D., Raynes D.A., et al. Development of a sensitive assay for the measurement of antibodies against heat shock protein binding protein 1 (HspBP1): increased levels of anti-HspBP1 IgG are prevalent in HIV infected subjects. J. Med. Virol. 2005;76:464&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pubmed">15977250</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillit H., Shibata S., Sasaki T., Spiera H., Kerr L.D., Blake M. Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity. 1993;14:243&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">8329561</ArticleId></ArticleIdList></Reference><Reference><Citation>Tiumentseva M., Morozova V., Zakabunin A., Korobko D., Malkova N., Filipenko M., et al. Use of the VH6-1 gene segment to code for anti-interleukin-18 autoantibodies in multiple sclerosis. Immunogenetics. 2016;68:237&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">26743536</ArticleId></ArticleIdList></Reference><Reference><Citation>Bremer H.D., Landegren N., Sjoberg R., Hallgren A., Renneker S., Lattwein E., et al. ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease. Sci. Rep. 2018;8:4852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5859008</ArticleId><ArticleId IdType="pubmed">29556082</ArticleId></ArticleIdList></Reference><Reference><Citation>Presslauer S., Hinterhuber G., Cauza K., Horvat R., Rappersberger K., Wolff K., et al. RasGAP-like protein IQGAP1 is expressed by human keratinocytes and recognized by autoantibodies in association with bullous skin disease. J. Invest. Dermatol. 2003;120:365&#x2013;371.</Citation><ArticleIdList><ArticleId IdType="pubmed">12603848</ArticleId></ArticleIdList></Reference><Reference><Citation>Idborg H., Zandian A., Sandberg A.S., Nilsson B., Elvin K., Truedsson L., et al. Two subgroups in systemic lupus erythematosus with features of antiphospholipid or Sj&#xf6;gren's syndrome differ in molecular signatures and treatment perspectives. Arthritis Res. Ther. 2019;21:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6378708</ArticleId><ArticleId IdType="pubmed">30777133</ArticleId></ArticleIdList></Reference><Reference><Citation>Targoff I.N., Trieu E.P., Miller F.W. Reaction of anti-OJ autoantibodies with components of the multi-enzyme complex of aminoacyl-tRNA synthetases in addition to isoleucyl-tRNA synthetase. J. Clin. Invest. 1993;91:2556&#x2013;2564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC443318</ArticleId><ArticleId IdType="pubmed">8514867</ArticleId></ArticleIdList></Reference><Reference><Citation>Ola T.O., Biro P.A., Hawa M.I., Ludvigsson J., Locatelli M., Puglisi M.A., et al. Importin beta: a novel autoantigen in human autoimmunity identified by screening random peptide libraries on phage. J. Autoimmun. 2006;26:197&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16549322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyachenko L., Havrysh K., Lytovchenko A., Dosenko I., Antoniuk S., Filonenko V., et al. vol. 2016. Disease markers; 2016. p. 5128720. (Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5099469</ArticleId><ArticleId IdType="pubmed">27847402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kain R., Tadema H., McKinney E.F., Benharkou A., Brandes R., Peschel A., et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J. Am. Soc. Nephrol. : JASN (J. Am. Soc. Nephrol.) 2012;23:556&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3294304</ArticleId><ArticleId IdType="pubmed">22323643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda K., Nakanishi T., Shimizu A., Takubo T., Matsuura N. Identification of L-plastin autoantibody in plasma of patients with non-Hodgkin's lymphoma using a proteomics-based analysis. Ann. Clin. Biochem. 2008;45:65&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">18275676</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunschweig D., Krakowiak P., Duncanson P., Boyce R., Hansen R.L., Ashwood P., et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl. Psychiatry. 2013;3:e277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731784</ArticleId><ArticleId IdType="pubmed">23838888</ArticleId></ArticleIdList></Reference><Reference><Citation>Konstantinov K.N., Galcheva-Gargova Z., Hoier-Madsen M., Wiik A., Ullman S., Halberg P., et al. Autoantibodies to lamins A and C in sera of patients showing peripheral fluorescent antinuclear antibody pattern on HEP-2 cells. J. Invest. Dermatol. 1990;95:304&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">2384689</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito J., Biamonti G., Caporali R., Montecucco C. Autoantibodies to human nuclear lamin B2 protein. Epitope specificity in different autoimmune diseases. J. Immunol. 1994;153:2268&#x2013;2277. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pubmed">7519647</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Kishimura M., Ozaki S., Osakada F., Hashimoto H., Okubo M., et al. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J. Clin. Invest. 2000;106:137&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC314355</ArticleId><ArticleId IdType="pubmed">10880057</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadoth A., Kryzer T.J., Fryer J., McKeon A., Lennon V.A., Pittock S.J. Microtubule-associated protein 1B: novel paraneoplastic biomarker. Ann. Neurol. 2017;81:266&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">28074593</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeulen N., Vermeire S., Arijs I., Michiels G., Ballet V., Derua R., et al. Seroreactivity against glycolytic enzymes in inflammatory bowel disease. Inflamm. Bowel Dis. 2011;17:557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">20629101</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K., Nagao T., Itabashi M., Hamano Y., Sugamata R., Yamazaki Y., et al. A novel autoantibody against moesin in the serum of patients with MPO-ANCA-associated vasculitis. Nephrol. Dial. Transplant. 2014;29:1168&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pubmed">24319012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinou D., Katsifis G., Barouta G., Liaskos C., Sakkas L.I., Tsakris A., et al.  Major vault protein/lung resistance related protein: a novel biomarker for rheumatoid arthritis. Clin. Exp. Rheumatol. 2020 https://www.clinexprheumatol.org/abstract.asp?a=15829 PMID: 33124564.</Citation><ArticleIdList><ArticleId IdType="pubmed">33124564</ArticleId></ArticleIdList></Reference><Reference><Citation>von Muhlen C.A., Chan E.K., Peebles C.L., Imai H., Kiyosawa K., Tan E.M. Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases. Clin. Exp. Immunol. 1995;100:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1534265</ArticleId><ArticleId IdType="pubmed">7697925</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaso&#x144;ska B.A., Hl&#xed;dkov&#xe1; H., Petrovsk&#xfd; E., Myronovskij S., Nehrych T., Negrych N., et al. Monodisperse magnetic poly(glycidyl methacrylate) microspheres for isolation of autoantibodies with affinity for the 46 kDa form of unconventional Myo1C present in autoimmune patients. Mikrochim. Acta. 2018;185:262.</Citation><ArticleIdList><ArticleId IdType="pubmed">29687337</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Z., Lavingia B., Zou Y., Stastny P. Antibodies against nucleolin in recipients of organ transplants. Transplantation. 2011;92:829&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">21869741</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Naour F., Brichory F., Misek D.E., Brechot C., Hanash S.M., Beretta L. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol. Cell. Proteomics : MCP. 2002;1:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">12096119</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Xing X., Huang H., Jiang Y., He H., Xu X., et al. Identification of antigenic proteins associated with trichloroethylene-induced autoimmune disease by serological proteome analysis. Toxicol. Appl. Pharmacol. 2009;240:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">19647757</ArticleId></ArticleIdList></Reference><Reference><Citation>Brankin B., Skaar T.C., Brotzman M., Trock B., Clarke R. Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol. Biomark. Prev. 1998;7:1109&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9865429</ArticleId></ArticleIdList></Reference><Reference><Citation>Devaux J.J., Odaka M., Yuki N. Nodal proteins are target antigens in Guillain-Barr&#xe9; syndrome. J. Peripher. Nerv. Syst. : JPNS. 2012;17:62&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">22462667</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagayama S., Yokoi T., Tanaka H., Kawaguchi Y., Shirasaka T., Kamataki T. Occurrence of autoantibody to protein disulfide isomerase in patients with hepatic disorder. J. Toxicol. Sci. 1994;19:163&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">7966454</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker A., Ludwig N., Keller A., Tackenberg B., Eienbroker C., Oertel W.H., et al. Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays. PloS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3587426</ArticleId><ArticleId IdType="pubmed">23483977</ArticleId></ArticleIdList></Reference><Reference><Citation>Houng A.K., Maggini L., Clement C.Y., Reed G.L. Identification and structure of activated-platelet protein-1, a protein with RNA-binding domain motifs that is expressed by activated platelets. Eur. J. Biochem. 1997;243:209&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">9030741</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneda K., Takasaki Y., Takeuchi K., Yamada H., Nawata M., Matsushita M., et al. Autoimmune response to proteins of proliferating cell nuclear antigen multiprotein complexes in patients with connective tissue diseases. J. Rheumatol. 2004;31:2142&#x2013;2150.</Citation><ArticleIdList><ArticleId IdType="pubmed">15517625</ArticleId></ArticleIdList></Reference><Reference><Citation>Caorsi C., Niccolai E., Capello M., Vallone R., Chattaragada M.S., Alushi B., et al. Protein disulfide isomerase A3-specific Th1 effector cells infiltrate colon cancer tissue of patients with circulating anti-protein disulfide isomerase A3 autoantibodies. Transl. Res. : J. Lab. Clin. Med. 2016;171:17&#x2013;28. e1-2.</Citation><ArticleIdList><ArticleId IdType="pubmed">26772958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Shen W., Dong X., Fan J., Liu L., Gao X., et al. Identification of novel autoantibodies for detection of malignant mesothelioma. PloS One. 2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3747111</ArticleId><ArticleId IdType="pubmed">23977302</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Liao D., Wang J., Liang Z., Yao Q. Anti-human protein S antibody induces tissue factor expression through a direct interaction with platelet phosphofructokinase. Thromb. Res. 2014;133:222&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947162</ArticleId><ArticleId IdType="pubmed">24331211</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczorek M., Czernik A. Paraneoplastic pemphigus: a short review. Clin. Cosmet. Invest. Dermatol. 2016;9:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042195</ArticleId><ArticleId IdType="pubmed">27729809</ArticleId></ArticleIdList></Reference><Reference><Citation>Mecoli C.A., Adler B.L., Yang Q., Hummers L.K., Rosen A., Casciola-Rosen L., et al. Arthritis &amp; rheumatology; Hoboken, NJ): 2020. Cancer in Systemic Sclerosis: Analysis of Antibodies against Components of the Th/To Complex.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884482</ArticleId><ArticleId IdType="pubmed">33241644</ArticleId></ArticleIdList></Reference><Reference><Citation>Loshaj-Shala A., Colzani M., Brezovska K., Poceva Panovska A., Suturkova L., Beretta G. Immunoproteomic identification of antigenic candidate Campylobacter jejuni and human peripheral nerve proteins involved in Guillain-Barr&#xe9; syndrome. J. Neuroimmunol. 2018;317:77&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">29338928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratz A., Harding M.W., Craft J., Mackworth-Young C.G., Handschumacher R.E. Autoantibodies against cyclophilin in systemic lupus erythematosus and Lyme disease. Clin. Exp. Immunol. 1992;90:422&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1554566</ArticleId><ArticleId IdType="pubmed">1458678</ArticleId></ArticleIdList></Reference><Reference><Citation>Karasawa R., Ozaki S., Nishioka K., Kato T. Autoantibodies to peroxiredoxin I and IV in patients with systemic autoimmune diseases. Microbiol. Immunol. 2005;49:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">15665454</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L.H., Xu Y.W., Huang L.S., Hong C.Q., Zhai T.T., Liao L.D., et al. Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin. Proteonomics. 2017;14:6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5289059</ArticleId><ArticleId IdType="pubmed">28184180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S., Hiwasa T., Arasawa T., Kagaya A., Ishii S., Shimada H., et al. Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. Oncotarget. 2018;9:18559&#x2013;18569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5915093</ArticleId><ArticleId IdType="pubmed">29719626</ArticleId></ArticleIdList></Reference><Reference><Citation>Schild-Poulter C., Su A., Shih A., Kelly O.P., Fritzler M.J., Goldstein R., et al. Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology. 2008;47:165&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">18208821</ArticleId></ArticleIdList></Reference><Reference><Citation>Heo C.K., Hwang H.M., Lim W.H., Lee H.J., Yoo J.S., Lim K.J., et al. Cyclic peptide mimotopes for the detection of serum anti-ATIC autoantibody biomarker in hepato-cellular carcinoma. Int. J. Mol. Sci. 2020:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7766137</ArticleId><ArticleId IdType="pubmed">33352757</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaughan J.H., Valbracht J.R., Nguyen M.D., Handley H.H., Smith R.S., Patrick K., et al. Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1. J. Clin. Invest. 1995;95:1306&#x2013;1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC441470</ArticleId><ArticleId IdType="pubmed">7533788</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo L.Y., Herrera I., Soosaipillai A., Diamandis E.P. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br. J. Canc. 2002;87:339&#x2013;343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2364218</ArticleId><ArticleId IdType="pubmed">12177805</ArticleId></ArticleIdList></Reference><Reference><Citation>Doe K., Nozawa K., Hiruma K., Yamada Y., Matsuki Y., Nakano S., et al. Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus. Lupus. 2014;23:1031&#x2013;1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">24836587</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagatsuma M., Kimura M., Suzuki R., Takeuchi F., Matsuta K., Ezrin H. Watanabe. Radixin and moesin are possible auto-immune antigens in rheumatoid arthritis. Mol. Immunol. 1996;33:1171&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">9070665</ArticleId></ArticleIdList></Reference><Reference><Citation>Scofield R.H., Harley J.B. Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus. Proc. Natl. Acad. Sci. U. S. A. 1991;88:3343&#x2013;3347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC51443</ArticleId><ArticleId IdType="pubmed">1849652</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato T., Uchiumi T., Kominami R., Arakawa M. Autoantibodies specific for the 20-KDal ribosomal large subunit protein L12. Biochem. Biophys. Res. Commun. 1990;172:496&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pubmed">2241950</ArticleId></ArticleIdList></Reference><Reference><Citation>Absi M., La Vergne J.P., Marzouki A., Giraud F., Rigal D., Reboud A.M., et al. Heterogeneity of ribosomal autoantibodies from human, murine and canine connective tissue diseases. Immunol. Lett. 1989;23:35&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2606513</ArticleId></ArticleIdList></Reference><Reference><Citation>Guialis A., Patrinou-Georgoula M., Tsifetaki N., Aidinis V., Sekeris C.E., Moutsopoulos H.M. Anti-5S RNA/protein (RNP) antibody levels correlate with disease activity in a patient with systemic lupus erythematosus (SLE) nephritis. Clin. Exp. Immunol. 1994;95:385&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1535070</ArticleId><ArticleId IdType="pubmed">8137536</ArticleId></ArticleIdList></Reference><Reference><Citation>Frampton G., Moriya S., Pearson J.D., Isenberg D.A., Ward F.J., Smith T.A., et al. Identification of candidate endothelial cell autoantigens in systemic lupus erythematosus using a molecular cloning strategy: a role for ribosomal P protein P0 as an endothelial cell autoantigen. Rheumatology. 2000;39:1114&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035132</ArticleId></ArticleIdList></Reference><Reference><Citation>Neu E., von Mikecz A.H., Hemmerich P.H., Peter H.H., Fricke M., Deicher H., et al. Autoantibodies against eukaryotic protein L7 in patients suffering from systemic lupus erythematosus and progressive systemic sclerosis: frequency and correlation with clinical, serological and genetic parameters. The SLE Study Group. Clin. Exp. Immunol. 1995;100:198&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1534346</ArticleId><ArticleId IdType="pubmed">7743655</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon K., Bonfa E., Llovet R., Danho W., Weissbach H., Brot N. Properties of the ribosomal P2 protein autoantigen are similar to those of foreign protein antigens. Proc. Natl. Acad. Sci. U. S. A. 1988;85:5186&#x2013;5189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC281713</ArticleId><ArticleId IdType="pubmed">2455896</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkon K., Weissbach H., Brot N. Central nervous system function in systemic lupus erythematosus. Neurochem. Res. 1990;15:401&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">1697040</ArticleId></ArticleIdList></Reference><Reference><Citation>Tycowski K.T., Shu M.D., Steitz J.A. A small nucleolar RNA is processed from an intron of the human gene encoding ribosomal protein S3. Gene Dev. 1993;7:1176&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">8319909</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J., Choi G., Li L., Wang H., Pitteri S.J., Pereira-Faca S.R., et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J. Clin. Oncol. : official journal of the American Society of Clinical Oncology. 2008;26:5060&#x2013;5066.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2652098</ArticleId><ArticleId IdType="pubmed">18794547</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J.M., Hildebrandt B., Luderschmidt C., Pollard K.M. Human scleroderma sera contain autoantibodies to protein components specific to the U3 small nucleolar RNP complex. Arthritis Rheum. 2003;48:210&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">12528121</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaji K., Fertig N., Medsger T.A., Jr., Satoh T., Hoshino K., Hamaguchi Y., et al. Autoantibodies to RuvBL1 and RuvBL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res. 2014;66:575&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">24023044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang H.M., Heo C.K., Lee H.J., Kwak S.S., Lim W.H., Yoo J.S., et al. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma. J. Transl. Med. 2018;16:177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6025833</ArticleId><ArticleId IdType="pubmed">29954402</ArticleId></ArticleIdList></Reference><Reference><Citation>Kistner A., Bigler M.B., Glatz K., Egli S.B., Baldin F.S., Marquardsen F.A., et al. Characteristics of autoantibodies targeting 14-3-3 proteins and their association with clinical features in newly diagnosed giant cell arteritis. Rheumatology. 2017;56:829&#x2013;834.</Citation><ArticleIdList><ArticleId IdType="pubmed">28064210</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi B.F., Bouillet L., Drouet M.T., Kuhn L., Garin J., Zarski J.P., et al. Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies. Eur. J. Clin. Microbiol. Infect. Dis. 2009;28:137&#x2013;146. official publication of the European Society of Clinical Microbiology.</Citation><ArticleIdList><ArticleId IdType="pubmed">18696130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo M., Ihn H., Kuwana M., Asano Y., Tamaki T., Yamane K., et al. Anti-U5 snRNP antibody as a possible serological marker for scleroderma-polymyositis overlap. Rheumatology. 2002;41:531&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pubmed">12011376</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto A.M., Amoura Z., Johannet C., Jeronimo A.L., Campos H., Koutouzov S., et al. Quantitative radioligand assays using de novo-synthesized recombinant autoantigens in connective tissue diseases: new tools to approach the pathogenic significance of anti-RNP antibodies in rheumatic diseases. Arthritis Rheum. 2000;43:689&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728764</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntriss J.D., Latchman D.S., Williams D.G. Lupus autoantibodies discriminate between the highly homologous Sm polypeptides B/B' and SmN by binding an epitope restricted to B/B. Clin. Exp. Immunol. 1993;92:263&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1554819</ArticleId><ArticleId IdType="pubmed">7683587</ArticleId></ArticleIdList></Reference><Reference><Citation>Brahms H., Raymackers J., Union A., de Keyser F., Meheus L., Luhrmann R. The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies. J. Biol. Chem. 2000;275:17122&#x2013;17129.</Citation><ArticleIdList><ArticleId IdType="pubmed">10747894</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain M.T., Ramsland P.A., Kaufman K.M., James J.A. Anti-sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J. Immunol. 2002;168:2054&#x2013;2062. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pubmed">11823543</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh M., Chan J.Y., Ross S.J., Ceribelli A., Cavazzana I., Franceschini F., et al. Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. Arthritis Rheum. 2011;63:1972&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3123691</ArticleId><ArticleId IdType="pubmed">21425128</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M., Gulati S., Smoot E., Jaffa M., Maher N., Hyman B.T., et al. vol. 12. 2011. Anti-superoxide dismutase antibodies are associated with survival in patients with sporadic amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis; pp. 430&#x2013;438. (Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446817</ArticleId><ArticleId IdType="pubmed">22023190</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbarz M., Dhermy D., Bournier O., Bezeaud A., Boivin P. Anti-spectrin in sera containing smooth muscle autoantibodies from patients with chronic active hepatitis. Clin. Exp. Immunol. 1981;43:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1537121</ArticleId><ArticleId IdType="pubmed">6788413</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaninoni A., Vercellati C., Imperiali F.G., Marcello A.P., Fattizzo B., Fermo E., et al. Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. Transfusion. 2015;55:2930&#x2013;2938.</Citation><ArticleIdList><ArticleId IdType="pubmed">26259504</ArticleId></ArticleIdList></Reference><Reference><Citation>Utz P.J., Hottelet M., Le T.M., Kim S.J., Geiger M.E., van Venrooij W.J., et al. The 72-kDa component of signal recognition particle is cleaved during apoptosis. J. Biol. Chem. 1998;273:35362&#x2013;35370.</Citation><ArticleIdList><ArticleId IdType="pubmed">9857079</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipes B.D., Keene J.D. vol. 8. RNA; New York, NY): 2002. pp. 762&#x2013;771. (Autoimmune Epitopes in Messenger RNA).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1370295</ArticleId><ArticleId IdType="pubmed">12088149</ArticleId></ArticleIdList></Reference><Reference><Citation>Santoro P., De Andrea M., Migliaretti G., Trapani C., Landolfo S., Gariglio M. High prevalence of autoantibodies against the nuclear high mobility group (HMG) protein SSRP1 in sera from patients with systemic lupus erythematosus, but not other rheumatic diseases. J. Rheumatol. 2002;29:90&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">11824977</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortini A., Bembich S., Marson L., Cocco E., Edomi P. Identification of novel non-myelin biomarkers in multiple sclerosis using an improved phage-display approach. PloS One. 2019;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6894809</ArticleId><ArticleId IdType="pubmed">31805175</ArticleId></ArticleIdList></Reference><Reference><Citation>Niland B., Miklossy G., Banki K., Biddison W.E., Casciola-Rosen L., Rosen A., et al. Cleavage of transaldolase by granzyme B causes the loss of enzymatic activity with retention of antigenicity for multiple sclerosis patients. J. Immunol. 2010;184:4025&#x2013;4032. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117466</ArticleId><ArticleId IdType="pubmed">20194725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.J., Ting W.H., Yang Y.W., Lin C.J., Hsieh Y.T., Huang C.Y., et al. HLA-DQ genotype and biochemical characterization of anti-transglutaminase 2 antibodies in patients with type 1 diabetes mellitus in Taiwan. Faseb. J. : official publication of the Federation of American Societies for Experimental Biology. 2020;34:8459&#x2013;8474.</Citation><ArticleIdList><ArticleId IdType="pubmed">32362042</ArticleId></ArticleIdList></Reference><Reference><Citation>Muto M., Mori M., Hiwasa T., Takiguchi M., Iwadate Y., Uzawa A., et al. Novel serum autoantibodies against talin1 in multiple sclerosis: possible pathogenetic roles of the antibodies. J. Neuroimmunol. 2015;284:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26025055</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariampillai K., Granger B., Amelin D., Guiguet M., Hachulla E., Maurier F., et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA neurology. 2018;75:1528&#x2013;1537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583199</ArticleId><ArticleId IdType="pubmed">30208379</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng X., Biancone L., Dai H.H., Lin J.J., Yoshizaki N., Dasgupta A., et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 1998;114:912&#x2013;922.</Citation><ArticleIdList><ArticleId IdType="pubmed">9558279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gajbhiye R., Sonawani A., Khan S., Suryawanshi A., Kadam S., Warty N., et al. Identification and validation of novel serum markers for early diagnosis of endometriosis. Hum. Reprod. 2012;27:408&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">22158085</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura A., Sakurai T., Yamada M., Koumura A., Hayashi Y., Tanaka Y., et al. Anti-endothelial cell antibodies in patients with cerebral small vessel disease. Curr. Neurovascular Res. 2012;9:296&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">23030505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X., Cheng Y., Gan Y., Jia R., Zhu L., Sun X. Anti-tubulin-alpha-1C autoantibody in systemic lupus erythematosus: a novel indicator of disease activity and vasculitis manifestations. Clin. Rheumatol. 2018;37:1229&#x2013;1237.</Citation><ArticleIdList><ArticleId IdType="pubmed">29427009</ArticleId></ArticleIdList></Reference><Reference><Citation>Matthes T., Wolff A., Soubiran P., Gros F., Dighiero G. Antitubulin antibodies. II. Natural autoantibodies and induced antibodies recognize different epitopes on the tubulin molecule. J. Immunol. 1988;141:3135&#x2013;3141. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pubmed">2459243</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasannan L., Misek D.E., Hinderer R., Michon J., Geiger J.D., Hanash S.M. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin. Canc. Res. : an official journal of the American Association for Cancer Research. 2000;6:3949&#x2013;3956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11051243</ArticleId></ArticleIdList></Reference><Reference><Citation>Muro Y., Ogawa Y., Kato Y., Hagiwara M. Autoantibody to thioredoxin reductase in an ovarian cancer patient. Biochem. Biophys. Res. Commun. 1998;242:267&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">9446782</ArticleId></ArticleIdList></Reference><Reference><Citation>Betteridge Z.E., Gunawardena H., Chinoy H., North J., Ollier W.E., Cooper R.G., et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 2009;68:1621&#x2013;1625.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930994</ArticleId></ArticleIdList></Reference><Reference><Citation>Almamy A., Schwerk C., Schroten H., Ishikawa H., Asif A.R., Reuss B. Interactions of antisera to different Chlamydia and Chlamydophila species with the ribosomal protein RPS27a correlate with impaired protein synthesis in a human choroid plexus papilloma cell line. Immunol. Res. 2017;65:1110&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">28913776</ArticleId></ArticleIdList></Reference><Reference><Citation>Pluta A.F., Earnshaw W.C. Specific interaction between human kinetochore protein CENP-C and a nucleolar transcriptional regulator. J. Biol. Chem. 1996;271:18767&#x2013;18774.</Citation><ArticleIdList><ArticleId IdType="pubmed">8702533</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Sun J., Mu R., Gan Y., Wang G., He J., et al. The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus. Clin. Exp. Rheumatol. 2019;37:474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">30418114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Cui J., Du H. Autoantibody-targeted TAAs in pancreatic cancer: a comprehensive analysis. Pancreatology. 2019;19:760&#x2013;768.</Citation><ArticleIdList><ArticleId IdType="pubmed">31255446</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyachi K., Hosaka H., Nakamura N., Miyakawa H., Mimori T., Shibata M., et al. Anti-p97/VCP antibodies: an autoantibody marker for a subset of primary biliary cirrhosis patients with milder disease? Scand. J. Immunol. 2006;63:376&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pubmed">16640662</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F.J., Surolia R., Li H., Wang Z., Kulkarni T., Liu G., et al. Autoimmunity to vimentin is associated with outcomes of patients with idiopathic pulmonary fibrosis. J. Immunol. 2017;199:1596&#x2013;1605. Baltimore, Md : 1950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5563167</ArticleId><ArticleId IdType="pubmed">28754682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mimori T., Ohosone Y., Hama N., Suwa A., Akizuki M., Homma M., et al. Isolation and characterization of cDNA encoding the 80-kDa subunit protein of the human autoantigen Ku (p70/p80) recognized by autoantibodies from patients with scleroderma-polymyositis overlap syndrome. Proc. Natl. Acad. Sci. U. S. A. 1990;87:1777&#x2013;1781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC53566</ArticleId><ArticleId IdType="pubmed">2308937</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoa S., Hudson M., Troyanov Y., Proudman S., Walker J., Stevens W., et al. Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. Medicine (Baltim.) 2016;95</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008592</ArticleId><ArticleId IdType="pubmed">27583908</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgenroth R., Reichardt C., Steffen J., Busse S., Frank R., Heidecke H., et al. Autoantibody formation and mapping of immunogenic epitopes against cold-shock-protein YB-1 in cancer patients and healthy controls. Cancers. 2020;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7759818</ArticleId><ArticleId IdType="pubmed">33255653</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunschweig D., Krakowiak P., Duncanson P., Boyce R., Hansen R.L., Ashwood P., et al. Autism-specific maternal autoantibodies recognize critical proteins in developing brain. Transl. Psychiatry. 2013;3:e277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731784</ArticleId><ArticleId IdType="pubmed">23838888</ArticleId></ArticleIdList></Reference><Reference><Citation>van Beers-Tas M.H., Marotta A., Boers M., Maksymowych W.P., van Schaardenburg D. A prospective cohort study of 14-3-3eta in ACPA and/or RF-positive patients with arthralgia. Arthritis Res. Ther. 2016;18:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4818496</ArticleId><ArticleId IdType="pubmed">27037016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarti R., Gupta K., Swain M., Willard B., Scholtz J., Svensson L.G., et al. vol. 67. Arthritis &amp; rheumatology; Hoboken, NJ): 2015. pp. 1913&#x2013;1921. (14-3-3 in Thoracic Aortic Aneurysms: Identification of a Novel Autoantigen in Large Vessel Vasculitis).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4624269</ArticleId><ArticleId IdType="pubmed">25917817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>